BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 35849868)

  • 61. ADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED RECTAL CANCER: DECIDING ON THE OPTIMAL STRATEGY.
    de Torres-Olombrada MV; Juez-Martel I; Rodríguez-Caravaca G; Duran-Poveda M
    Rev Invest Clin; 2020; 72(2):88-94. PubMed ID: 32284624
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status.
    Read TE; Andujar JE; Caushaj PF; Johnston DR; Dietz DW; Myerson RJ; Fleshman JW; Birnbaum EH; Mutch MG; Kodner IJ
    Dis Colon Rectum; 2004 Jun; 47(6):825-31. PubMed ID: 15108025
    [TBL] [Abstract][Full Text] [Related]  

  • 63. MRI predictive factors for tumor response in rectal cancer following neoadjuvant chemoradiation therapy--implications for induction chemotherapy?
    Yu SK; Tait D; Chau I; Brown G
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):505-11. PubMed ID: 24074924
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Indistinguishable T2/T3-N0 rectal cancer on rectal magnetic resonance imaging: comparison of surgery-first and neoadjuvant chemoradiation therapy-first strategies.
    Kim JG; Song KD; Cha DI; Kim HC; Yu JI
    Int J Colorectal Dis; 2018 Oct; 33(10):1359-1366. PubMed ID: 30003363
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Adjuvant Chemotherapy Use in Patients With Locally Advanced Rectal Cancer: A Single-Institution Experience.
    Li F; Nielsen G; Baran A; Hu J; Wallace D; Preslar M; Fleming F; Temple L; Dunne RF; Noel M; Hezel AF; Tejani MA
    Clin Colorectal Cancer; 2020 Sep; 19(3):e124-e128. PubMed ID: 32409226
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prognostic Implications of Pathological Response to Neoadjuvant Chemoradiation in Pathologic Stage III Rectal Cancer.
    Karagkounis G; Thai L; Mace AG; Wiland H; Pai RK; Steele SR; Church JM; Kalady MF
    Ann Surg; 2019 Jun; 269(6):1117-1123. PubMed ID: 31082910
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation.
    Schollbach J; Kircher S; Wiegering A; Anger F; Rosenwald A; Germer CT; Löb S
    Int J Colorectal Dis; 2020 Feb; 35(2):365-370. PubMed ID: 31828368
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term Clinical Outcomes of Nonoperative Management With Chemoradiotherapy for Locally Advanced Rectal Cancer in the Veterans Health Administration.
    Spiegel DY; Boyer MJ; Hong JC; Williams CD; Kelley MJ; Moore H; Salama JK; Palta M
    Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):565-573. PubMed ID: 30359718
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Long-term outcome of local excision after preoperative chemoradiation for ypT0 rectal cancer.
    Stipa F; Picchio M; Burza A; Soricelli E; Vitelli CE
    Dis Colon Rectum; 2014 Nov; 57(11):1245-52. PubMed ID: 25285690
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
    Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
    Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
    Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
    World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
    Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
    Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Survival landscape of different tumor regression grades and pathologic complete response in rectal cancer after neoadjuvant therapy based on reconstructed individual patient data.
    Li JY; Huang XZ; Gao P; Song YX; Chen XW; Lv XE; Fu Y; Xiao Q; Ye SY; Wang ZN
    BMC Cancer; 2021 Nov; 21(1):1214. PubMed ID: 34773999
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
    Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
    Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
    Gollins S; Sun Myint A; Haylock B; Wise M; Saunders M; Neupane R; Essapen S; Samuel L; Dougal M; Lloyd A; Morris J; Topham C; Susnerwala S
    J Clin Oncol; 2011 Mar; 29(8):1042-9. PubMed ID: 21263095
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiotherapy.
    Smith FM; Wiland H; Mace A; Pai RK; Kalady MF
    Dis Colon Rectum; 2014 Mar; 57(3):311-5. PubMed ID: 24509452
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Adjuvant chemotherapy after neoadjuvant chemoradiation and curative resection for rectal cancer: is it necessary for all patients?
    Jung KU; Kim HC; Park JO; Park YS; Park HC; Choi DH; Cho YB; Yun SH; Lee WY; Chun HK
    J Surg Oncol; 2015 Mar; 111(4):439-44. PubMed ID: 25488390
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Adjuvant Chemotherapy After Preoperative Chemoradiation Improves Survival in Patients With Locally Advanced Rectal Cancer.
    Sun Z; Gilmore B; Adam MA; Kim J; Hsu SD; Migaly J; Mantyh CR
    Dis Colon Rectum; 2017 Oct; 60(10):1050-1056. PubMed ID: 28891848
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Thymidine phosphorylase and hypoxia-inducible factor 1-α expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis.
    Lin S; Lai H; Qin Y; Chen J; Lin Y
    Int J Clin Exp Pathol; 2015; 8(9):10680-8. PubMed ID: 26617778
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Usefulness of Restaging Pelvis Magnetic Resonance Imaging After Neoadjuvant Concurrent Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.
    Fahmawi Y; Smith C; Grimm L; Khullar S; Rider P; Hunter J; Iliff G; Mneimneh W; Roveda K; Wang B; Prodduturvar P; Alkharabsheh O; McCormick B; Mizrahi M; Khushman M
    Clin Colorectal Cancer; 2020 Dec; 19(4):e281-e287. PubMed ID: 32694005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.